UFP Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing also reports fourth-quarter results. UFP Technologies designs and manufactures custom products, primarily for medical devices and sterile packaging, with additional automotive, aerospace and defense, and industrial businesses. The company reports as one operating segment.
Financial performance
| Metric | FY2023 | FY2022 | Change or context |
|---|---|---|---|
| Net sales | $400.1 million | $353.8 million | Up 13.1% |
| Gross profit / margin | $112.2 million / 28.1% | $90.3 million / 25.5% | Margin improved 2.6 percentage points |
| Operating income / margin | $57.7 million / 14.4% | $55.4 million / 15.7% | Income up 4.1%; margin lower |
| Net income | $44.9 million | $41.8 million | Up 7.5% |
| Diluted EPS | $5.83 | $5.45 | Up 7.0% |
| Cash from operations | $41.3 million | $17.7 million | Higher, despite working-capital investment |
| Capital expenditures | $10.5 million | $13.8 million | Cash used for equipment and facility improvements |
| Cash and cash equivalents | $5.3 million | $4.5 million | At year-end |
| Long-term debt | $32.0 million | $55.0 million | $4.0 million current; $28.0 million long-term |
Year-end current assets were $144.6 million and current liabilities were $58.2 million. The company’s $130 million secured credit agreement includes a $40 million term loan and a revolving facility of up to $90 million, and matures in December 2026. The applicable rate was approximately 6.7% at year-end; the company reported compliance with its financial covenants. Cash used in financing activities was $30.0 million, principally reflecting revolving-credit repayments, debt principal, earn-out payments, and share-based tax withholding.
Material changes and quarterly results
- Medical-market sales grew 21.0%, led by robotic surgery products and increased surgical procedures. Medical represented 86.6% of FY2023 sales, compared with 80.9% in FY2022.
- Sales to all other markets decreased 20.6%, which the company attributed largely to the July 2022 sale of its Molded Fiber business.
- Gross margin improved with organic growth, operating efficiencies, and lower overhead as a share of sales. Management cited progress integrating recent acquisitions and capturing synergies.
- SG&A rose 11.1% to $50.9 million, but declined as a share of sales to 12.7% from 12.9%. Net interest expense increased to $3.6 million from $2.8 million, primarily because of higher average interest rates.
- FY2023 included a $3.5 million expense from remeasurement of contingent consideration. FY2022 results included a $15.7 million gain on the Molded Fiber sale and a $6.1 million gain on disposal of fixed assets, as well as a $9.8 million contingent-consideration expense; these items affect year-over-year comparability.
- Fourth-quarter 2023 sales were $101.5 million and net income was $11.6 million, versus $91.2 million and $8.5 million, respectively, in fourth-quarter 2022. Q4 2023 gross profit was $26.1 million, versus $23.3 million. FY2022 Q3 net income included a $15.7 million Molded Fiber sale gain.
Outlook, risks, and contingencies
- Management said demand softened late in 2023 as some customers worked through excess inventory and characterized the softness as short-term. The filing provides no quantified revenue or earnings guidance.
- The company expects operating cash, existing resources, and its revolving facility to fund requirements, including capital asset purchases, through the next 12 months. It plans to add manufacturing capacity and may pursue further acquisitions, but cautions that future cash generation, covenant compliance, and access to financing are not assured.
- Customer concentration is significant: one customer generated approximately 28% of 2023 sales, and the top ten generated approximately 59%. Two customers represented approximately 16.5% and 12.2% of year-end gross receivables.
- Inventory increased $16.6 million to $70.2 million, and receivables increased $9.1 million to $64.4 million. Management attributed the inventory build to anticipated demand and higher receivables to stronger late-year sales; these balances merit monitoring given the reported customer inventory digestion.
- Remaining DAS Medical earn-out liability was valued at $13.1 million at year-end, with up to $15 million of potential payments remaining. The company also reported $8.5 million present value of non-compete payment obligations. The estimates are Level 3 fair values and may change with business performance and assumptions.
- Other stated risks include inflation and labor costs, variable-rate debt, reliance on limited suppliers for certain foams, product quality and regulatory compliance, international operations, cybersecurity, and acquisition integration. Goodwill and other intangible assets totaled $177.4 million, about 44% of total assets.
- An employee claim was pending; management did not expect it to have a material adverse effect. The filing reports an ongoing IRS audit and a $0.67 million uncertain tax benefit related to disputed prior-year research credits.
Investor verification priorities
- Track the largest customer’s sales and receivables exposure, customer inventory levels, and the extent to which late-2023 demand softness continues.
- Assess whether the inventory build converts into sales and cash, and monitor receivables collections and operating cash flow.
- Review gross-margin durability, including the contribution from organic growth, integration synergies, and manufacturing efficiencies.
- Verify debt paydown, variable-rate interest exposure, revolving-facility availability, and covenant headroom.
- Monitor earn-out remeasurement and payments, acquisition-related obligations, and the carrying value of goodwill and other intangible assets.
- Note that the financial statements received an unqualified audit opinion, the auditor reported no critical audit matters, and management and the auditor concluded internal control over financial reporting was effective at December 31, 2023.